Amicus Therapeutics Inc (NASDAQ: FOLD) established initial surge of 1.07% at $9.42, as the Stock market unbolted on Wednesday, before settling in for the price of $9.32 at the close. Taking a more long-term approach, FOLD posted a 52-week range of $5.51-$10.83.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 34.10%. Meanwhile, its Annual Earning per share during the time was 34.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 87.04%. This publicly-traded company’s shares outstanding now amounts to $308.50 million, simultaneously with a float of $301.63 million. The organization now has a market capitalization sitting at $2.91 billion. At the time of writing, stock’s 50-day Moving Average stood at $8.39, while the 200-day Moving Average is $7.58.
Amicus Therapeutics Inc (FOLD) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Amicus Therapeutics Inc industry. Amicus Therapeutics Inc’s current insider ownership accounts for 2.24%, in contrast to 101.99% institutional ownership. According to the most recent insider trade that took place on Nov 04 ’25, this organization’s Chief People Officer sold 25,643 shares at the rate of 9.51, making the entire transaction reach 243,860 in total value, affecting insider ownership by 322,618.
Amicus Therapeutics Inc (FOLD) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.1 per share during the current fiscal year.
Amicus Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 87.04% and is forecasted to reach 0.27 in the upcoming year.
Amicus Therapeutics Inc (NASDAQ: FOLD) Trading Performance Indicators
Let’s observe the current performance indicators for Amicus Therapeutics Inc (FOLD). It’s Quick Ratio in the last reported quarter now stands at 2.09. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.85. Similarly, its price to free cash flow for trailing twelve months is now 299.94.
In the same vein, FOLD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.04, a figure that is expected to reach 0.07 in the next quarter, and analysts are predicting that it will be 0.27 at the market close of one year from today.
Technical Analysis of Amicus Therapeutics Inc (FOLD)
Now, what If we examine the latest scores posted by [Amicus Therapeutics Inc, FOLD]. During the last 5-days, its volume was better the volume of 4.19 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 61.44% While, its Average True Range was 71.67.
Raw Stochastic average of Amicus Therapeutics Inc (FOLD) in the period of the previous 100 days is set at 94.67%, which indicates a major rise in contrast to 80.95% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.39 that was higher than 0.30 volatility it exhibited in the past 100-days period.
